97 related articles for article (PubMed ID: 31161518)
1. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
[TBL] [Abstract][Full Text] [Related]
2. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.
Kato C; Fujii N; Miyakoshi C; Asada S; Onishi Y; Fukuma S; Nomura T; Wada M; Fukagawa M; Fukuhara S; Akizawa T
BMC Nephrol; 2020 Oct; 21(1):432. PubMed ID: 33045994
[TBL] [Abstract][Full Text] [Related]
3. The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping.
Xu H; Peng W; Yang Z; Zhang Y; Xia C; Li Z; Xu R; Guo Y
J Cardiovasc Magn Reson; 2021 Mar; 23(1):23. PubMed ID: 33691727
[TBL] [Abstract][Full Text] [Related]
4. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
Asada S; Yokoyama K; Miyakoshi C; Fukuma S; Endo Y; Wada M; Nomura T; Onishi Y; Fukagawa M; Fukuhara S; Akizawa T
Clin Exp Nephrol; 2020 Jul; 24(7):630-637. PubMed ID: 32236781
[TBL] [Abstract][Full Text] [Related]
5. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
6. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients.
Kalantar-Zadeh K; Miller JE; Kovesdy CP; Mehrotra R; Lukowsky LR; Streja E; Ricks J; Jing J; Nissenson AR; Greenland S; Norris KC
J Bone Miner Res; 2010 Dec; 25(12):2724-34. PubMed ID: 20614473
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease.
Strugnell SA; Csomor P; Ashfaq A; Bishop CW
Kidney Dis (Basel); 2023 May; 9(3):206-217. PubMed ID: 37497207
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial.
Shigematsu T; Koiwa F; Isaka Y; Fukagawa M; Hagita K; Watanabe YS; Honda D; Akizawa T
Clin J Am Soc Nephrol; 2023 Oct; 18(10):1300-1309. PubMed ID: 37696667
[TBL] [Abstract][Full Text] [Related]
9. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation.
Tabibzadeh N; Karaboyas A; Robinson BM; Csomor PA; Spiegel DM; Evenepoel P; Jacobson SH; Ureña-Torres PA; Fukagawa M; Al Salmi I; Liang X; Pisoni RL; Young EW
Nephrol Dial Transplant; 2021 Jan; 36(1):160-169. PubMed ID: 33068419
[TBL] [Abstract][Full Text] [Related]
10. Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis.
Zheng FY; Tan YY; Zhou JJ
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):96-102. PubMed ID: 37814913
[TBL] [Abstract][Full Text] [Related]
11. Radiofrequency ablation for patients with recurrent or persistent secondary hyperparathyroidism after parathyroidectomy: initial experience.
Jiang T; Deng E; Chai H; Weng N; He H; Zhang Z; Li D; Yue W; Peng C; Xu HX
Endocrine; 2024 Mar; 83(3):681-690. PubMed ID: 37725290
[TBL] [Abstract][Full Text] [Related]
12. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America.
Cozzolino M; Shilov E; Li Z; Fukagawa M; Al-Ghamdi SMG; Pisoni R; Bieber B; Vallabh B; Chand DH
Adv Ther; 2020 Jun; 37(6):2748-2762. PubMed ID: 32410164
[TBL] [Abstract][Full Text] [Related]
13. Low Parathyroid Hormone
Guo W; Zhang H; Zhang Y; Huang H; Liu W; Diao Z
Front Endocrinol (Lausanne); 2022; 13():869330. PubMed ID: 35634511
[TBL] [Abstract][Full Text] [Related]
14. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.
Daugirdas JT; Chertow GM; Larive B; Pierratos A; Greene T; Ayus JC; Kendrick CA; James SH; Miller BW; Schulman G; Salusky IB; Kliger AS;
J Am Soc Nephrol; 2012 Apr; 23(4):727-38. PubMed ID: 22362907
[TBL] [Abstract][Full Text] [Related]
15. [The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment].
Eremkina AK; Elfimova AR; Aboisheva EA; Karaseva EV; Fadeeva MI; Maganeva IS; Kovaleva EV; Gorbacheva AM; Bibik EE; Mokrysheva NG
Probl Endokrinol (Mosk); 2022 Aug; 68(4):52-58. PubMed ID: 36104966
[TBL] [Abstract][Full Text] [Related]
16. Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis.
Fishbane S; Hazzan AD; Jhaveri KD; Ma L; Lacson E
Clin J Am Soc Nephrol; 2016 Jun; 11(6):1063-1072. PubMed ID: 27026521
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal study on the change trend of serum alkaline phosphatase and its possible influencing factors in peritoneal dialysis patients.
Zhao W; Zhang S; Zhao HD
Sci Rep; 2024 Jun; 14(1):13099. PubMed ID: 38849443
[TBL] [Abstract][Full Text] [Related]
18. Associated factors of osteoporosis and vascular calcification in patients awaiting kidney transplantation.
Lv J; Xie W; Wang S; Zhu Y; Wang Y; Zhang P; Chen J
Int Urol Nephrol; 2023 Dec; 55(12):3217-3224. PubMed ID: 37093441
[TBL] [Abstract][Full Text] [Related]
19. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.
Cruzado JM; Lauzurica R; Pascual J; Marcen R; Moreso F; Gutierrez-Dalmau A; Andrés A; Hernández D; Torres A; Beneyto MI; Melilli E; Manonelles A; Arias M; Praga M
Kidney Int Rep; 2018 Jan; 3(1):122-132. PubMed ID: 29340322
[TBL] [Abstract][Full Text] [Related]
20. A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients.
Villa-Bellosta R; Rodriguez-Osorio L; Mas S; Abadi Y; Rubert M; de la Piedra C; Gracia-Iguacel C; Mahillo I; Ortiz A; Egido J; González-Parra E
PLoS One; 2017; 12(3):e0173831. PubMed ID: 28339474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
